Spirax Group plc (SPX) Earnings Call Transcript
March 11, 2025
Earnings Call Speaker Segments
Hi everyone, and thank you for being here for Spirax Group's 2024 results presentation. Louisa Burdett is with me today, and you're all familiar with her by now. In fact, this marks the first results announcement that Louisa has delivered in her role as our CFO. I want to begin by recognizing the enormously positive contribution she has made to our group since coming on board last July. Now let me give you an overview of how we performed in 2024. Each of our three businesses achieved organic growth, and margins came in as we had anticipated. Group organic sales growth for the full year reached 4%, which was comfortably above global IP of 1.7%. That growth came despite a tough trading backdrop, which was defined by, first, third-party IP forecasts being cut over the course of the year as macroeconomic risks shifted. Specifically, the second-half rebound in IP that had been projected never showed up. Second, a substantial headwind affecting our STS business in China, something I flagged at this point 12 months ago. Third, BioPharma orders recovering more slowly and gradually than we had anticipated when the year began. And finally, meaningful currency headwinds weighing on both growth and margins. With all of that in mind, we concentrated on delivering the operational priorities we can control and on pushing forward with executing our strategy.
I'm quite encouraged by the solid upward momentum in ETS. For this business, our top objective is lifting the margin to 20% while realizing its strong growth potential. With manufacturing throughput improving, organic sales rose 10% and margin improved to 16%. We see a substantial pipeline of customer inquiries tied to our electrification solutions for decarbonization. We're on track to hit our targets. In STS, organic sales growth came in at 1%, yet outside China we posted robust growth of 4% against a comparable IP of 0.8%. At Watson-Marlow, which grew organically by 3%, process industries showed strong growth that offset broadly flat BioPharma sales. In each case, we achieved growth by concentrating on our target sectors and executing on solution selling. We safeguarded margins in 2024 via ongoing pricing discipline and efficiency savings. Group margin reached 20.1% even with the partial reversal of prior-year cost containment actions. Crucially, we raised investment in our future growth. Cash conversion returned to a higher level at 87%, helped by working capital improvement and reduced capital expenditure, which mirrors our emphasis on maximizing utilization of manufacturing capacity. After stating our intent at the October Capital Markets event, we've also acted decisively to simplify the organization and better position the group to achieve long-term, highly profitable organic sales growth.
Louisa and I will have more to say on that later, but the restructuring effort kicked off quickly in January and is on track. It has now been slightly more than a year since I took on the CEO role, and the headway we have achieved over that period gives me a lot of encouragement. What we have done will leave us better placed to hit our financial targets down the road and to realize our growth potential going forward. Above all, I want to express my thanks to my colleagues worldwide for their dedication while we carried out the operational priorities that were within our control. I mentioned that the trading environment has been difficult. Let me elaborate now on the conditions we confronted in 2024. Thermal energy management, of course, is required in virtually every industrial production process, and we operate in nearly every sector and region globally. Growth in global IP serves as a key leading indicator for our businesses, since customers align their production capacity, productivity, and efficiency with the demand they expect. In the same way, we intend to beat IP growth by executing our business model and our strategy. Thanks to our local direct sales force and our deep knowledge of customer processes, we assist them in enhancing cost efficiency during tough periods, and we assist them in boosting productivity and capacity when conditions are favorable.
Keeping that in mind, let's move now to the IP forecasts. For the full year, global IP growth came in at 1.7%, and it was a much weaker 0.8% when China is excluded. The chart at the top left illustrates how forecasts were revised downward over the course of the year. After weak IP growth during the first half, the anticipated improvement in the second half never showed up, as the top-right chart makes clear. Excluding China, actual growth was 1%. This pattern wasn't confined to a small set of sectors or countries; instead, it points to broader caution among customers. IP has stayed lower for longer than we and many others anticipated. In key markets—the U.S., Germany, France, Italy, and the U.K., which together account for over 50% of group sales—we saw industrial production decline relative to 2023. As far back as we have consistent and reliable data, this is only the third time in four decades that all of these markets have contracted simultaneously. As for China, IP forecasts are still uncertain, with providers holding a wide range of expectations. What we observe in China is a meaningful slowdown in the expansion of customers' manufacturing capacity, given mounting barriers to global trade. Turning to 2025, CHR's forecast for global IP is 2.1%, or 1.9% excluding China.
For the first half, excluding China, we're forecasting growth of 1.7%. Then growth is weighted toward the second half, at 2.1%. That calls for healthy sequential growth, quarter on quarter, above what we achieved in last year's second half. In today's highly uncertain macroeconomic environment, these forecasts follow a familiar pattern. We're taking a cautious approach to IP in 2025. We recognize that IP is likely to be weaker in the short term, with potential for further disruption from tariffs and other geopolitical events. Wherever it eventually lands, we're confident that we will continue to outperform IP in 2025. We're monitoring the tariff situation closely and assessing the impact on our operations. In all three businesses, we manufacture in the U.S.A. to meet a significant proportion of domestic demand. Through a combination of this regional manufacturing, changes to sourcing, and our price management, we're prepared to respond to the effects of tariffs. The precise impact is difficult to gauge while uncertainty remains high, particularly around the broader consequences for the macroeconomic outlook. I also recognize that an important part of our group and Watson-Marlow, namely our BioPharma business, has been going through a period of volatility. We felt that this year it was important to share some additional insight to help explain our sales growth and our guidance.
Just to remind everyone, BioPharma makes up 12% of the group and 50% of Watson-Marlow's sales. During 2024, we began to see new order intake from BioPharma customers recovering, with double-digit growth, though that came off a low base. That came after orders had fallen by more than 50% by the end of 2023 from the COVID-related peak in 2021. We saw solid growth in end-user customer orders and sales, which represent roughly three-quarters of total BioPharma sales. Large OEM customers also showed improvement from a low base, though with considerable volatility from month to month. Orders from large OEM customers improved, but sales to those customers fell. If you look at the chart on the right-hand side of this slide, you'll see that total BioPharma sales in 2024 exceeded orders, as has been the case in recent years, helped by the large carried-forward order book. Our order book has now normalized. What that means is that from here on, sales growth will come from new order intake. Now, while we expect double-digit recovery in BioPharma orders to continue, it is coming off a low base, so sales growth will lag orders growth. Hopefully that gives you some insight into the rather complex moving parts and also why we expect BioPharma to recover more gradually.
The fundamental forces behind BioPharma demand are still strong, which is evident in the end-user activity we are observing. At this point I'll pass things to Louisa, who will go into greater detail on how we performed financially in 2024 and lay out what we expect for 2025.
Thank you, Nimesh, and good morning to everyone. I want to flag a couple of presentation items before I begin. The figures we'll cover today are the adjusted results, and you'll find a reconciliation of statutory to operating profit in the appendix. When we talk about organic growth, our definition leaves out the impact of currency movements on both sales and profit. Naturally, there was no M&A during the period. As we had guided, currency movements in the year came in at -5% on sales and -8% on operating profit. Our full-year figures matched the expectations we laid out at our half-one results. At the group level, sales rose 4% versus the prior year, comfortably ahead of IP and supported by growth across all three of our businesses. Operating profit likewise increased 4% organically, and our operating margin of 20.1% was up 10 basis points on an organic basis. Net financing costs came in slightly below our guidance of GBP 45 million, though GBP 4 million higher year-on-year, reflecting the annualized effect of a higher coupon rate on debt that was refinanced at the end of 2023. As anticipated, our effective tax rate rose 100 basis points to 26.5%. Adjusted EPS came in at 286.3 pence per share, down 8% year-on-year.
That figure exceeded the drop in operating profit, which stemmed from a larger net finance expense and a rise in the effective tax rate. Our full-year dividend is going up by 3%, a sign of confidence that we will get back to stronger growth and better margins. Turning to the sales bridge on the following slide, as mentioned, currency movements hurt full-year sales by GBP 74 million, or 5%. Within STS, organic sales for the full year rose 1%. After a 1% fall in the first half, the business came back with 3% growth in the second. To put those first-half and second-half growth rates in context, keep in mind that the first half of 2023 gave us a tough comparison because of China's post-COVID expansionary investment phase, and demand weakened afterwards in the second half of 2023. In ETS, organic sales for the full year were up a pleasing 10%, with a strong second-half showing of 15%. That comes from operational improvements in process heating, which Nimesh will discuss later. Watson-Marlow's organic sales rose 3%, and as we expected, BioPharma sales were roughly flat in absolute terms against 2023, though with some volatility from month to month. Sales to process industry customers, which track IP more closely, held up well all year, especially in the second half.
The next page's bridge walks through the movements in adjusted operating profit for the year. Currency movements had an effect — a negative one — of GBP 28 million, or 8%. Profit in steam rose 1% organically, matching the 1% organic growth in sales. In 2023, we tempered our investment in steam, but in 2024 we aimed to keep an appropriate mix of cost, with discipline on the base overhead, while safeguarding investment for the future. The operating margin in STS, at 23.5%, was broadly flat organically year on year. In ETS, profit was up 13% organically, with stronger growth in the second half, driven by improvements at our Ogden manufacturing facility as well as good progress at Volcanic. That growth was partly offset by ongoing investment to deliver those operational improvements and by some historic orders that could not be repriced for inflation. The full-year operating margin in ETS came in at 16%, up 50 basis points organically. We saw strong margin improvement in process heating year on year, but lower margins year on year in equipment heating, as higher Semicon did not meaningfully recover. Watson-Marlow delivered organic profit growth of 11% and a 180 basis points increase in margin, benefiting from the operating leverage of the increase in sales.
On corporate costs, those came to 2% of group sales, and that reflects higher investments aimed at backing key strategic initiatives in digital and sustainability. Moving to cash flow, our rate of converting operating profit into cash stood at 87%, which came about through working capital improvements as well as choices we made regarding capital expenditure. Capital expenditure reached GBP 84 million, equal to 5% of group sales. Beyond the maintenance capital we normally spend, we put GBP 29 million into our new low and medium voltage production facility in Ogden, and that site is set to come online in the early second half of this year. In the second half of 2024, we took two active decisions regarding our capital program. The first: as part of reviewing our manufacturing footprint and capacity, we paused construction of a new manufacturing facility in Gestra, Germany. The second: apart from Thermocoax France, we pushed back our planned ERP spend while we aligned around the concept of a global common design covering all three businesses. Nimesh will expand on these two points later in our update when we discuss operational excellence. Over recent years, we have put investment into expansion projects at Watson-Marlow and ETS. We are now emerging from that stretch in which capital expenditure ran higher than our historic rates.
Looking ahead to 2025, we expect capital expenditure to land in the neighborhood of 5%-6% of sales. Within that CapEx mix for 2025, ERP costs will rise, though this will be partly offset by reduced spending on that Ogden building now that the investment is wrapping up. Turning to 2024, we were encouraged to see our working capital-to-sales ratio strengthen by 1%-21.9% on a constant currency basis, driven by attention to inventory and overdue receivables. We closed the year with net debt down to GBP 596 million, equal to 1.6x EBITDA. Next, on the following slide, I'll walk you through several of the main drivers behind our operational performance and, in that context, share our 2025 guidance, which we are providing for the first time today. A lot of the themes from 2024 carry over into 2025. Starting with STS on the left: for 2024, organic sales growth outside China reached 4% for the full year, far exceeding global IP excluding China at 0.8%. We've spoken before about large orders declining in China after the post-COVID period of expansionary investment. Consequently, China sales in 2024 came in 13% lower, versus representing 17% of STS in 2023. MRO sales did grow by double digits during 2024, yet they aren't yet offsetting that ongoing softness.
Then once more, Nimesh is going to walk through several of the steps we're taking to genuinely push that MRO pivot forward. Turning to STS and looking ahead to 2025, we anticipate that trading conditions in China will stay difficult. We're additionally observing how global instability is affecting Korea, which ranks as STS's second biggest market in Asia. Growth ahead of IP across our remaining markets will make up for softer trading in China and Korea. Combining those two factors, we expect steam to produce low single-digit organic sales growth, with margin staying broadly level with 2024. Turning next to ETS in the middle, we've already discussed our strong operational progress in process heating during 2024, and we're also seeing early signals that Semicon demand is improving from a low base. With both of these trends continuing, in 2025 we anticipate mid to high single-digit organic sales growth for the ETS business. Margin progress will carry on as well, though the costs tied to the new building in Ogden will temper how quickly margin expands until we reach full volume. Last, on the right with Watson-Marlow, Nimesh has already noted that total BioPharma sales stayed above orders in 2024, since we were carrying forward that large order book.
We did start to see the first signs of improvement in new order intake, coming off a very low base, and that trend continues to back up our belief that the recovery will be gradual and U-shaped. For the Watson-Marlow business overall in 2025, we expect mid-single-digit organic sales growth, and that comes from the assumed ongoing recovery in BioPharma orders plus process industries performing better than IP. That should produce high single-digit organic profit growth and a margin increase versus 2024. Moving to the next slide, at the group level, our guidance is on an organic basis, and it rests on restating our 2024 results for the effect of exchange rate movements in 2025. Were exchange rates from the beginning of March to hold for the rest of the year, 2024 sales would come in roughly 2% lower at GBP 1,637 million, and 2024 adjusted operating profit roughly 4% lower at GBP 320 million, giving an FX adjusted margin of 19.6%. That FX headwind stems from the pound strengthening against several currencies in our trading basket. For 2025, we expect organic growth in group revenues in line with what was achieved in 2024, with somewhat higher growth in the second half.
For 2024, group adjusted operating profit margin should come in above the 19.6% currency adjusted margin I mentioned a moment ago, alongside mid-single-digit organic growth in adjusted operating profit. As we highlighted at our capital markets day, please keep in mind that we anticipate a variable compensation charge returning in 2025, totaling roughly GBP 15 million to GBP 20 million in aggregate across our three businesses and in corporate. We got off to a good start in 2024, and we continue to target procurement savings in 2025, which should deliver savings in the mid-teen millions and will partly offset these incremental remuneration charges returning to the P&L. Our corporate costs will be approximately GBP 40 million, reflecting higher investments in growth initiatives that are centrally funded. Those investments, along with others inside the three businesses, will be funded by the restructuring program we noted in our R&S today. This program will deliver annualized savings of approximately GBP 35 million, with about 40% of that achieved in 2025. Cash costs to deliver the program are expected to be approximately GBP 35 million, plus non-cash costs of about GBP 5 million, so GBP 40 million in total, focused on improving our organizational efficiency and closing some manufacturing sites across the world.
Nimesh is going to go into more detail on those two items in just a moment. Those GBP 40 million of exceptional costs sit outside our adjusted operating profit, and they're also excluded from the margin guidance we've given. Last thing from me: please turn to the appendix — sorry — where you'll find additional group guidance items covering financing costs, ETR, CapEx, and cash conversion. On my closing slide, I simply restate the medium-term margin target we're aiming for, which is a 22%-23% operating profit margin while we keep investing in a sensible way. At the capital markets day event, we set out the four building blocks that make up this multi-year bridge. First, organic growth of roughly 200 basis points. Second, about 150 basis points of financial benefit stemming from operating improvements. Third, roughly 100 basis points of incremental investments to underpin our longer-term growth. Fourth, procurement savings that are targeted to help offset variable compensation coming back in 2025. Every one of these actions remains in place, and we've begun delivering against them in 2025, which is the first year of this medium-term plan. Our focus stays on those medium-term goals, and Nimesh will now walk you through how we're delivering the objectives of our Together for Growth strategy. Thank you.
Thanks, Louisa. I'd like to take a quick moment to remind everybody about the path we're on, which we laid out at the Capital Markets event in October. Our goal is clear: to achieve the medium-term targets Louisa just walked through, and as shown on the right-hand side of this slide, over the long term we anticipate going even further — strengthening organic growth, margins, and shareholder returns over the long haul. On the left-hand side of this slide, a reminder that we have three powerful growth engines, all built on one shared business model, and that model has let us produce consistent organic growth ahead of IP across many years and through numerous economic cycles. Our direct sales engineers sell value-creating solutions that solve customers' problems. We're evolving this differentiated model so we're more connected with customers locally, directly, and digitally, the aim being to anticipate and meet their needs, which keep getting more complex. In the middle of this slide, you'll see there's a very substantial addressable market opportunity ahead of us, and we're well positioned to capture it through our Together for Growth strategy, which comes down fundamentally to two things. First, we'll speed up the rate at which organic growth compounds over the long term by making targeted investments, and those will let us capture the significant opportunities we see ahead, generating attractive returns.
That covers putting money into digital and services, plus our distinctive know-how in thermal energy efficiency and decarbonization. The funding capacity for those investments is going to come from self-help, by concentrating on our operational priorities — be it commercial excellence, how we strengthen our sales capacity and capability; operational excellence, how we get more productive and efficient in manufacturing; or organizational fitness, how we work better across the organization so we serve customers more effectively and get more from our resources. Delivery is already moving along well, as the next slide shows, laying out what we achieved in 2024 and what we'll prioritize in 2025. What underpins my confidence in capturing the opportunity ahead is the leadership team. Stuart Roby most recently came aboard as Managing Director of Watson-Marlow, after I asked Andrew Mines to head up ETS. Over 50% of this new team is either new or new in role, and it combines a deep understanding of the group with fresh ideas and an experienced outside perspective alongside that — all of which will help our execution. Let me now sum up the progress made in these early days of executing our strategy, beginning with the operational priorities and commercial excellence.
During 2024, we added more sales colleagues who work directly with customers. Within STS and Watson-Marlow, focusing our sales efforts by sector helped us achieve growth considerably above IP, and we gained market share in those targeted sectors. We are bolstering our standing in emerging high-growth sectors by drawing on the know-how of regional teams to back up colleagues — from China in the electric vehicle battery sector, for instance — as our customers look into new places to manufacture. We brought out new products, such as WMArchitect from Watson-Marlow, which supports self-generated solution selling in the BioPharma sector via bespoke approaches to linking disparate systems along the fluid pathway. Qdos H-FLO, a pump for chemical metering and dosing, extends our addressable market further in process industries. Shortly, I will also share an example of how we are expanding MRO sales from our installed base in STS. During 2025, we are concentrating on getting the most productivity from our direct sales engineers, which includes raising customer-facing time and the count of customer visits to generate growth in a weaker macroeconomic environment. Turning now to operational excellence: over 2024, we began realizing procurement savings both within and across all three businesses, and we will keep growing those savings in 2025. We also consolidated our manufacturing footprint in the U.S.A., shutting a number of smaller manufacturing sites in ETS and Watson-Marlow.
This is the first step toward optimizing our footprint, and it keeps in place the regional manufacturing that matters so much for delivering strong customer service. We're concentrating mainly on smaller sites, or on places where we make more standard products. Earlier this year, we announced that our STS facility in Mexico would close, with production shifting to the U.S.A., and we're putting on hold the new Gestra facility in Germany that had previously been planned. As progress comes, we'll have more flexibility in how we manage that manufacturing footprint, and we'll keep reviewing the best way to optimize our fixed capital and extract value from it. Moving to organizational fitness: in January 2025, we began a series of organizational changes. We're cutting management layers and consolidating activity so it can be better leveraged across operating companies regionally. Take, for example, our product technical expertise, our field servicing and repair teams, and our digital services skills. These were built individually in larger operating companies, and now they'll serve as a center of excellence for all local companies in the region, based on where the opportunity is greatest. These organizational changes are being supported with common processes built into our systems. Turning briefly to ERP: during 2024, we went from three separate business-led programs to aligning around a single global common design.
During the second half, we finished the ERP rollout at Thermocoax in France successfully. That initiative had already been in progress, yet it gave us the chance to validate core design principles before we built out our shared framework. I'm genuinely happy with how quickly we've shifted into execution on our operational priorities, and this restructuring marks the first major effort of its kind that our group has ever taken on. Louisa walked you through the financial upside, which is substantial and will back our investment in future growth. What I'd like to stress is what comes from creating an organization that's simpler, more agile and more scalable, with streamlined internal processes and more time in front of customers for our sales teams. This slide takes a closer look at two key areas that influenced how we performed in 2024. Earlier, I discussed the challenge STS faced in China as customers reduced the pace of expanding manufacturing capacity, with those large projects representing 60% of sales. I believe it's useful to walk through how we've been reworking this business as an illustration of commercial excellence and of generating growth in MRO. Drawing on expertise from inside STS, China has by now finished mapping its sizable installed base to target the most appealing growth opportunities, brought in MRO-focused sales engineers in bigger regions where opportunities are more concentrated, and also developed and rolled out training so engineers focused on large projects can spot and self-generate MRO solutions, while realigning their incentives as well.
So because of that, MRO sales growth in China during 2024 reached the double digits, and we anticipate another year of double-digit growth in 2025. Naturally, MRO carries more attractive margins since customers fund it out of OpEx budgets rather than CapEx. The second example on this slide concerns operational excellence centered on our Ogden plant, where all through 2024 we've concentrated on raising shipments against a robust order book. As you're aware, boosting manufacturing throughput is an essential step toward achieving a 20% margin in ETS. Just to remind everyone, Ogden produces large low-voltage and medium-voltage heaters, which additionally underpin our decarbonization solutions. On the slide, there's a photo of a triple-stack heater shipped recently for a mission-critical application at a chemical customer's site. Only a handful of such heaters have been built over the past decade, and we've manufactured nearly all of them thanks to our dependable performance in the field. Our operational improvement at Ogden began with leadership changes in ETS and the local team. We're concentrating on enhancing key processes so customers' bespoke requirements are met without sacrificing efficiency and lead times. These include putting controls in place over complex designs and improving the interface between sales, engineering, and manufacturing that had created production challenges in the past.
When we tackle this quote-to-cash workflow, we cut lead times in design engineering, we plan resources and schedule production more effectively, and we gain better command over customer change requests—which translates into greater throughput and stronger efficiency. Following several years in which output stayed flat, we achieved a meaningful gain in shipments. Chromalox sales rose by a double-digit margin, Ogden shipments climbed by close to 40%, and that drove an overdue backlog reduction of over 20%, along with better margins thanks to operating leverage. Looking ahead to 2025, we anticipate additional gains. On a separate note, work to expand the Ogden facility—which focuses on producing medium-voltage solutions—is moving along nicely, stays on schedule to wrap up during 2025, and should further shorten lead times. Now let's take a quick look at a few of the areas we're targeting to fuel that growth down the road. These are longer-dated investments that pay off across multiple years, and 2024 saw solid progress on them. First up, digital and services. We're strengthening customer relationships by connecting with them even more closely, in person and now through digital means as well. That way, we walk the plant, and we walk the data. During 2024, we grew paid-for digital customer connections to over 10,000 assets—mainly STS steam traps and heat exchangers—spanning 1,000 customer sites.
In Watson-Marlow, we successfully trialed our machine-learning-enabled Bredell connected pump in the wastewater sector, predicting blockages in the fluid path. To give you an example of the return on investment, an international brewery customer asked us to help resolve significant steam loss. Typically, customers complete steam trap surveys annually, meaning failures remain undetected for long periods. Through our ecoBolt steam trap monitoring, we see process performance and energy consumption and detect failures in critical operations. Every failed trap costs over GBP 3,000 in energy loss and 13 tons in CO2 emissions over a year, and we were able to replace those traps within weeks, growing our MRO sales. You see how we've become even more knowledgeable on our customers' processes, increased the frequency of engagement, and thereby are able to anticipate their needs. Our work with this customer has also led to additional solution sales beyond these steam traps. Turning to the progress we're making on our decarbonization opportunity, which is delivered by combining complementary expertise from STS and ETS to significantly expand our addressable market. The focus of our investment here is on technology and capability. During 2024, we continue to refine our proprietary technology to decarbonize the generation of steam through electrification and ETS technology, launching additional pilots.
Our solutions portfolio grew through an investment in an emerging technology—high-temperature heat pumps for steam generation. We also advanced nicely on creating new resistive heating products capable of running at higher voltages and temperatures. In the same way, we completed the design of our decarbonization operating model, which, as you'll remember, is an essential first step toward making sure we have the right resources and structures to use our STS and ETS resources effectively. During 2025, across both digital and decarbonization, we'll keep going with our proof-of-concept pilots. So, pulling it all together, here's how I'd sum up our 2024 performance. We faced substantial external macroeconomic headwinds by concentrating on what we can control to deliver organic growth well ahead of IP, with margins across all three of our businesses matching our expectations. We're a new leadership team that has gelled well, developing our growth strategy, setting our financial objectives, and aligning the organization behind our operational and investment priorities. I'm proud of our colleagues who rose to the challenge, as the results reflect—including delivering on our guidance for the second half of 2024, increasing manufacturing throughput in ETS, delivering growth well ahead of IP in STS outside China and in Watson-Marlow process industries, and in the first part of 2025, we've taken early action on restructuring.
I'm confident we've got a clear plan that can be executed and the right team focused on delivering it. Moving to 2025, we aren't anticipating a meaningfully better trading environment, and as I've mentioned, we're taking a cautious view of the outlook for IP. With that as the backdrop, we're confident of making further good progress this year as we keep focusing on what we can control. For 2025, we expect organic growth in group revenues in line with what was achieved in 2024 and well ahead of IP, and group adjusted operating profit margin to be ahead of the 19.6% margin in 2024 on a currency-adjusted basis, which will drive mid-single-digit organic growth in adjusted operating profit. Through our together-for-growth strategy, we continue building the platform from which we'll deliver on our medium-term financial objectives and long-term compounding organic growth at attractive margins while also making progress in 2025. Thank you. We're happy to take your questions. I'll start at the back. Jonathan. Yes. Good morning. Hi. This is Jonathan Herman Barkes. I just have three questions, if I may. First, just on BioPharma, and apologies if I've missed it, but in terms. You might need to hold the mic a little closer. Sorry. Can you hear me now?
Was that any clearer? Yeah. Please talk a bit louder. Yeah. To start, my question concerned only BioPharma, and I apologize if I overlooked that. Regarding the recovery in orders that we are seeing, could you give us a sense of it? Does it lean toward the aftermarket, or does it lean toward your original equipment? If it does lean toward that aftermarket, may we assume that a mixed effect will show up in the margin benefit from Watson-Marlow going forward as a result? That was the first item. The second item concerned the new capacity that you are adding, or installing, at Ogden with respect to the spending involved. You are pointing out that it clearly weighs on the margin. Could you give us a sense of how long that weight will last? Basically, when does that facility reach an acceptable level of capacity utilization? My third question concerned steam. Clearly, you are pointing out that China is difficult, while the other two regions are outperforming. Could you say a little about U.S. steam and what you are seeing there, perhaps the growth rates? Clearly, within that, you are aiming for more of a direct sales approach rather than going through distributors.
Could you give us an update on how that's progressing and what impact it's having? Thanks. All right, thanks, Jonathan. I'll handle the first and third questions. Louisa, perhaps you can take the second one. Regarding BioPharma recovery, we're beginning to see new order intake improving across the board. A common way to think about the leading indicators in BioPharma is to look at long lead time items needed for capacity expansion. You'll frequently see that in our Flexicon systems shipped out of Europe. We're starting to see more inquiries for those products, often largely in fill and finish within BioPharma, since there's roughly a 12-month, 18-month lead time for delivery of those systems. We're seeing that improve. We're seeing demand for pumps improving, and that's often the second lead indicator, which is somewhat nearer term. You don't need to place those orders so far ahead, but it's a solid signal of greater activity at customer sites and likely some expansion of capacity within existing footprint. The third area we examine is consumables, as you mentioned, Jonathan, which concerns how much those processes are running at full capacity and whether people are beginning to churn through single-use tubing, for instance, or replacing pump heads.
We're seeing improvement across each of those three areas, right? BioPharma order intake is beginning to reflect what we expected all along — that really strong underlying growth still present in the sector. The pickup is especially noticeable among end-user customers. I realize there's plenty of disclosure coming from the bigger OEMs, which you'll naturally be watching closely. Demand from those larger OEMs tends to be more volatile. Quite often it's also more tied to capacity expansion than our business is. Last year we saw considerable month-on-month volatility in the large OEMs, yet order improvement is showing up in large OEM demand too. It's happening across the board. Getting those orders back to prior levels off a low base will take some time. That's the reason we've consistently guided toward a more gradual recovery in BioPharma, and that's what we continue to stand by. Would you like to take the Ogden point?
Okay, absolutely. Just a quick reminder that the plant ought to be starting up around July of this year. Order demand is still robust. We won't get into how much coverage that represents, but the direction is favorable. Jonathan, our view is that it will likely be putting some pressure on margins through 2026. Keep in mind that a major factor in reaching our 20% margin target for ETS by 2027 is throughput, productivity, and the volume leverage those assets provide. Getting comfortable with that new facility is going to take some time. We're quite encouraged by what we refer to as our end-to-end quote-to-cash revitalized process. Our teams are now examining everything from the moment a customer receives a quote all the way to when cash is collected, which historically has not been our strongest performance at Ogden. In fact, that ought to mean that as new work comes in, the flow should improve and we'll encounter fewer bumps along the way.
All right, question three. You're correct. Within the U.S., we've been aiming to generate demand more directly alongside our customers. Let me add a nuance here. Direct sales and generating direct demand are not the same thing. I'll clarify what I mean by that. We have several strategic distribution partners in the U.S., and we collaborate quite closely with them to call on the end customer. Through that, we apply our solution selling approach. We walk the plant, spot the opportunities, and assist customers in understanding ways to optimize their processes. How they subsequently place those orders is something I believe we can be more relaxed about. If placing them via the distributor makes sense for them, I think that's fine.
When we have those strategic distributor relationships, we think about how the value created gets shared, since they bring in the customer and we contribute expertise. Both sides generate value. The goal is growing the pie, not dividing a shrinking pie into different proportions. How do we increase the overall size of the pie? What I find brilliant about what's happening in the U.S. — and we've particularly accelerated this journey over the course of 2024, also under new leadership in the U.S. business — is that we're now looking at cogeneration, meaning both direct sales and working with those distributors the way I just described. That accounts for roughly half of total sales in the U.S. Keep in mind, direct was about 30%, meaning direct sales. Now, adding cogeneration to that brings us to a total of about 50%. I think we'll keep growing that portion of the business as we build more of these strategic distribution relationships. Keep in mind, the distribution business benefits us because our products are critical, emission-critical processes. Our customers need to be able to obtain products quickly.
If they’re unable to do that, our products won’t get used by them. Distribution works well since it lets us keep that inventory positioned across a country as big as the U.S.A. What comes out of that is we’ve had genuinely strong expansion in the Americas, in STS, and especially in the U.S., and we anticipate that will keep going. Thank you. Andy.
Morning to you both. Andrew Douglas here, from Jefferies. I have a handful of questions, if I may. Could we begin with STS in China? I am simply attempting to map out a route that brings China STS back into positive territory. From my perspective, it appears the declines in China sped up during the second half. It appears to me that OE was down roughly 25%. Do we expect MRO to catch up on growth rates so as to offset that, or do we expect OE declines to moderate, or some combination of the two? What does that imply for the timing where China is concerned? I will ask them one at a time.
All right, that helps a lot. Thanks. I'll begin with China, and Louisa, feel free to jump in. As I mentioned before, the key point to keep in mind is that roughly 60% of demand comes from the expanded and refurbished side, and that's where we're observing the pullback. Rebalancing MRO against expand and refurbish is going to take some time. MRO grew at a double-digit rate last year, and we expect the same this year. That should help bring the two into balance, likely at some point during 2026. Right? On top of that, MRO is going to keep growing as we continue building out that platform and capability in China. What will also happen is that expand and refurbish will begin to level off and flatten, and at some stage it will probably return to growth. When you combine all of those factors, that's what brings us back to growth in China. I'm not in a position to give you an exact date, but you can see that we're feeling somewhat more positive about 2026. One more thing worth noting, which we hadn't brought up earlier, is that we've taken cost actions in China. We've tackled the cost base while also making sure we're shifting resources toward MRO.
First, the margin point. Second, just to repeat, MRO margins exceed those on expand and refurbish. Viewed through profitability, that is a healthy thing for our business.
Nothing further to add.
The second question concerns ERP. I understand this is a significant undertaking, and you need to approach it carefully. Given that the three businesses differ, is one shared approach really suitable across all of them? Could you give us a rough estimate of what this entire ERP system will cost over the next however many years it takes? To me, it feels like that's going to be a large number.
I’ll have Louisa handle that question. As some background, you may recall that during the capital markets day I discussed how the way we’re organized supports ERP implementation. Let me repeat that point so it’s clear to everyone. In my view, ERP isn’t something you roll out everywhere all at once. We don’t need to do that. Given how our organization is structured, you saw what we recently completed with Thermocoax France. Right? It was delivered successfully, with minimal disruption, and at a reasonable cost within one of our businesses. We didn’t have to handle Thermocoax as a whole. We didn’t have to handle ETS as a whole. We didn’t have to roll it out across an entire group. Because that’s possible for us, we can spread the cost, and we can spread the risk—and the operational impact—of implementing ERP over a long period of time. Honestly, the way I see ERP is that it’s an ongoing cost of doing business, not a big one-off project. We’ll incur a cost every year for ERP. And you know what? Once we reach the end of this one, we’ll likely begin again at the back end, because it will be time to update the systems once more.
It's producing returns too. Take Thermocoax, for instance — with what we've accomplished there so far, we're going to boost productivity and efficiency at that site as well. That's the route to getting those returns over time. Louisa, would you like to say a little about the global common design?
Look, first of all, I'd say you brought up appropriateness. We believe this provides us with maximum optionality. It isn't solely about the business model. It's about common security and, sort of, common data environments, which give us a bit more flexibility. If we think about the approach for each of the businesses, we really are trying to — well, this isn't about a system. This is about how we do work. This is about changing the way we work. That's where the benefit comes. Standard functionality, standard ways of paying invoices, all of that stuff, that's a no-brainer. Actually pushing into manufacturing. There are lots of companies that do manufacturing with standard out-of-the-box ERP things. We are no more complex than other companies. We are really pushing ourselves to be, where do we really need to be different? We will respect where we need to be different, but we are taking quite a hard edge on maximizing the returns from what will be a big number. You're probably in the three-digit million type environment. To Nimesh's point, we are spreading that so that we are minimizing risk and minimizing capital expenditure. I can't emphasize enough the appropriateness comes from us getting sort of more balanced about how we do things in a similar way rather than this system.
Do those costs sit in the line or below it? Right now, the design cost we share for 2025 will land in CapEx. Where we record them is going to hinge on the contract, but as things stand, they're included in the CapEx figures.
That’s my final question, and I’ll return afterward.
Sorry, let me just add one thing to that, to reassure everybody. Those costs are already included in our CapEx guidance, as well as in the cash conversion guidance we provided at the capital markets day.
Alright, cool. On the costs being added back, you mentioned GBP 15 million to GBP 20 million. Is that the total figure, or should we expect more coming back in 2026? I understand that as volume recovers, you'll be putting costs back in, but this is more about that specific cost number. That's all, and I'll come back.
The investments are coming back in. Across the areas we discussed today—digital, sales, engineer effectiveness, target zero, decarb, and operational improvements—we're broadly balancing the investments as the operational improvements emerge. There will broadly be imbalance, though they won't be perfectly imbalanced. As you saw from the medium-term bridge, it's 150 basis points over the medium-term savings, with 100 basis points back to investment. We'll get some different balances. In the short term, a bit more of the benefits are staying in steam. Broadly, I'd say one-to-one. From a modeling perspective, in the short term, it does not.
I believe Andy's question is about the compensation. You mentioned GBP 15 million to GBP 20 million. What you're referring to is the variable comp returning.
Oh, my mistake. I heard 15 — I figured you meant the investment. I'm replying to something else entirely. What's your take?
That one was useful regardless.
I apologize — could you say that question again? 15 to.
Will the variable comp also apply in 2026, or not?
Yes, it’ll be in the base. Basically, my view is that you’ve got that variable cost returning, and then you’ve got the procurement savings in the base to cover it.
All right, thanks.
Morning, everyone. Lush Mahindra Raja here from JP. I’ve got two or three questions, I think. First, just on ETS and specifically Chromalox, since you mentioned backlog is down 20% for the year. I’m not sure how you define it, but how much more does it need to fall to reach normalized levels—whatever normalized means? And how much of that sits inside your mid- to high single-digit guidance for ETS growth? In other words, is that guidance supported mainly by Chromalox backlog declining, with not much included for semis or underlying growth? Yeah, that’s the first question. I assume Ogden will help absorb some of that too. Take them one at a time, or.
Sure, thank you for that question. We're actively reducing the overdue backlog specifically, and as a result, moving our backlog toward a more normalized level. An order book, or a backlog, depends on two factors. It depends on order intake — new order intake — and the amount of demand out there, plus how quickly we ship. The other thing we're observing is genuinely strong order intake, driven by the push toward electrification that we've discussed for some time now. A lack of demand that would prevent us from continuing to drive ETS growth is not something I'm worried about. That isn't what keeps me up at night, or anyone on the team for that matter. As for what's driving the ETS forecast for 2025, it's that operational improvement. We've placed less emphasis on the Semicon recovery. We saw it in Q4 of last year, picking up on the orders side. I'd venture to say we will keep seeing — I hope we'll keep seeing — further recovery in Semicon orders as this year goes on.
Sure, somewhat similar to BioPharma, it's starting from a low base, though we don't lean too heavily on that to hit our guidance. All right. Thanks. The next item is really a follow-up regarding ERP. In the ETS statement, you mention the rollout at Thermocoax in France, which was something of a margin headwind during the year. I suppose what exactly was that? Is it simply disruption from the switch to ERP? How should we think about it as you extend it to the larger sites and throughout the division? Is that a headwind we should factor in, and what about the phasing of it?
What matters here is that we deployed ERP at Thermocoax — a single instance, one site, and the cost was about normal for an implementation of that kind. We flagged it as one of the factors dampening margin in 2024 within equipment heating. It's small beer. It's enough to be noticeable, but it comes down to the law of small numbers. As you move that into 2025, what will largely be coming back in 2025 for Thermocoax is mostly the CapEx and the depreciation.
Let me be clear — this isn't about production disruption. The margin impact came purely from the cost of implementing ERP. That's essentially built into your investment guide. It is. Yeah. Okay. Yeah. Thank you. Third, on SDS, I believe you mentioned that pricing might normalize somewhat this year, given the levels we've seen lately. I suppose when you say that, is it roughly back to the 3%? You discussed the CMD in terms of historical pricing and all that. Sorry, I'm trying to answer the question. Your question is, by how much did we raise prices? In 2025, I think you mentioned that SDS pricing might be normalizing a little. Is that roughly back to 3%, which is what you've done historically? Back in line with the weighted average cost inflation we have. Yeah. Okay. Thank you. No problem. Should I come to — where's the microphone? You've got it. Shall we go to Maggie, and then pass the microphone to the front? Do you want just? Thank you.
Thanks. Maggie Schooley here from Redburn, with just a single question. Regarding ETS and the order book, you mentioned that some repricing for inflation happened this year. It had to be reduced. Repricing for inflation wasn't possible for you. Considering how long that order book is, do you expect any additional difficulties when it comes to repricing parts of that order book, or do you believe that issue has worked its way through? How should we think about this during this year, and has that already been included in your margin guidance?
Right. So first, that's factored into the margin guidance we gave. Second, you're correct that on orders which were past due, we can't go back to the customer and reprice them for inflation. We've continued shipping against those orders. That's the reason the impact looks smaller than you'd perhaps anticipate given very high growth, though on the margin improvement side, we still have some additional improvement ahead across 2025, although it is clearly diminishing as time goes on. And just one last thing, sorry. You've discussed digital quite a bit and how digital is driving growth. Could you share some detail on what you've observed, at least as we've moved into the first half of the year, regarding that digital rollout and how it's energizing orders, or is it not? Is it still slow? How should we think about that as a leader in terms of getting your order growth? Good question. Digital is driving growth, and in steam we expect it to drive even higher growth in 2025. Look, when we discuss outside China, we have that particular headwind Andy asked about earlier. Outside China, in steam, we're looking at 4% growth, right, in an IP environment of 0.8%.
So how are we delivering that massive outperformance relative to IP in a tough environment, given that we operate in every country and every sector worldwide? IP affects us too—we're not shielded from it. The way we get there is through exactly that kind of thing: engaging more effectively with customers, having superior data, meeting their needs better, and delivering the solutions. That's the method. Digital is one tool that supports us in doing so. On digital, here's what we observe: first, there's revenue from paid-for connections, though that piece is small. What we truly observe is product pull-through, such as the MRO example I mentioned. Digital, we can see, is helping propel our growth. Once we genuinely scale up those digital platforms we possess and add more connected products across our three businesses, what we're able to accomplish will be even bigger than what we're already delivering. Thank you. Mark has waited very patiently. I'll hand it over down here, and after that we'll move to the row. Thank you, Mark. Many thanks. A broad question first, then one that's a bit more specific. Clearly, we're living in interesting times. U.S. trade policy appears to be invented each morning and revised by tea time. I completely understand why you can't provide us with any view on tariffs, but presumably the effect of this is hitting your customers' CapEx decisions and their capacity to determine where to invest.
Do you observe any of this on the CapEx side of the business? I suppose the particular point is that you mentioned South Korea as a newly emerging weak spot. Is that due to the fact that it is another market, much like China, that leans more toward CapEx for steam? All right. Yes, uncertainty is running high, and it shifts daily. We are noticing an effect on how our customers make decisions. Right now, what we observe I would probably describe as decisions being deferred. That comes as no shock. As they wait to find out how some of these discussions unfold on the global stage, that does not help. It does not help the IP outlook. It does not help as a driver of our business. I would also point out that, looking at our business as a whole, roughly 15% comes from customer CapEx budgets and 85% from OpEx budgets. One benefit we have is that even when customers say, "Okay, we may postpone making the CapEx decision, we still need to achieve either cost efficiencies or greater throughput within our existing footprint," we can assist them with both. That is where our efforts are concentrated. What I described as taking place in MRO in China is in fact taking place throughout the steam business to ensure that we are leveraging digital, that we are spotting the MRO opportunities, that we are generating growth in MRO, and that we are applying our solution mindset to MRO too, very much in the manner I described with that international brewing customer.
On South Korea, I remember it was December when I switched on the TV and saw what was going on there, and we reached out to our local teams and worked fast to get a handle on how it would hit us. Korea is an interesting market for us, since a very robust EPC footprint exists there that supports not just Korean industry but customers elsewhere around the world too. How much Korea is affected depends on CapEx effects. It depends on their support globally, especially oil and gas in the Middle East. It depends on domestic conditions. It's not the same as China, right? It isn't weighted as heavily as China. We'll see an effect in Korea from local political instability and probably more widely from the CapEx impacts. All of that is reflected in our guidance.
Hello, this is Rory calling from Oxcap, and I appreciate your time in addressing my questions. There are a couple of things I want to ask about margins, Louisa, and this may actually be the one you were hoping to handle earlier. When we consider that GBP 35 million in restructuring that's underway, with roughly 40% falling in this year, as you seem to expect, would you be prepared to give a figure for 2026 and 2027 showing how it tapers off? Does all of it go back into reinvestment at 100%, or should we expect some sort of hockey stick effect on margins resulting from it? That's where I'll stop for now.
I appreciate the chance to respond to the question I didn't get asked initially. We stated that 40% of the 35 lands this year, roughly speaking, with the remainder arriving next year. A small amount comes in afterward, tied to certain manufacturing actions with longer timelines. As a general rule, that split is 40/60. Regarding our investment, again, broadly speaking, across the medium term, 150 basis points out and 100 back, with the timing depending on where we believe we must be most agile to generate the greatest return. Once more, as a principle, some items we are attempting to front-load. Nimesh has mentioned that digital sales engineers need a couple of years to reach full effectiveness. We have moved quickly on the restructuring. We intend to keep doing so with investment. You will understand that we don't wish to provide a year-by-year pattern of precisely where we will invest. We would like to preserve that agility.
Keep in mind that the medium-term guidance we provided is our attempt to see past some of that year-on-year volatility. Over the medium term, we will reach a 22%-23% margin. That instantly gives you a sense of where we might stand in 2026. We won't be at that target. We'll be under that target, but we will make progress toward it, right? Likewise, we've given you guidance on the growth we expect across all of our businesses as well.
Got it, thanks. So 2027 may end up being a year where things get better. On that point, and inside ETS, we've discussed the second-half pickup in new medium voltage capacity that's coming online, plus the higher throughput on the low voltage side. When it comes to quote to cash and the kinds of changes you've made there, how much of that medium voltage order book was booked under the old setup? In other words, do you have line of sight to the margins sitting in the order book for the medium voltage piece? I suppose what we're really asking is whether ETS margins should improve in a linear way, or whether it'll be uneven on the way to that 20% target in 2027. Thank you.
Are you asking if I'll take that one? My sense is that the bulk of that order book came from the old regime, though naturally a transition is involved. The team described 2025 — especially the second half — as a period of becoming effective, since Nimesh made the management changes only early in that second half. For 2025 and 2026, the focus is efficiency and profitability. There's more to come, but a few things deserve a word of caution from me. I've mentioned Rocky Mountain — the volume leverage when it arrives. Apologies, I've slipped again: New Austin, that's the project name we use for it.
That's the mountain, and that's the Rocky Mountain.
And one more thing, since I still have the floor here: we came out of the period with 15% growth across ETS overall, clearly driven by process heating efficiency as well as that pickup in Semicon. In fact, when it comes to the 2023 comparables, the Chromalox facility wasn't delivering the way it should have back in 2023. So you're seeing somewhat of a bump in that growth rate. That's the reason our guidance sits in the mid to high figures instead of carrying the 15% forward. Just something encouraging to keep in mind.
I appreciate you taking my questions.
Thanks. Come around to this side, please. Thank you, Mark from RBC. This is really a bit of a follow-up to the short reply given to Louisa's question about pricing and steam. I guess steam, on the face of it, showed a very weak organic drop-through on growth last year. Is that simply because sales or volumes organically were also lower during the year? My assumption is that pricing came in above 1%, though perhaps that is wrong. How should we view that price-volume mix for steam in 2025, given that kind of low single-digit growth? Does it imply volumes in steam will again be fairly flat? Yes. Thanks, Mark. Sorry. A few things are going on in steam. Why was the drop-through weaker in 2024? First, as we both mentioned, the temporary cost containment measures introduced in 2023 were reversed during 2024. For instance, putting more money into future growth and strengthening our sales capability — all of that took place in 2024. You are seeing that effect dampen the growth. What we are essentially referring to now with variable comp is an additional effect in 2025. The second point is that I believe you are right. If you look at the business as a whole, when you examine the price-volume balance, since we have 1% overall growth for steam, you would conclude that volume is lower, and that is a fair conclusion.
But you need to take China out of the equation, since volumes there are lower for the reasons we've already gone through. Look at the 4% figure that excludes China. What you'll find is that volumes are in fact higher. Flipping that over to Watson-Marlow, where organic drop-through was evidently quite strong. My impression — and tell me if I've got this wrong — is that the 30%+ margin target relates more to operating leverage than to the other parts of the business. Before COVID, that was in fact pretty reliably at a 32%-34% type margin. Do you see any structural reason why the business has shifted since that time? Is it simply that we're waiting for leverage on growth? Against that backdrop, what counts as a normal drop-through level for that business? Okay. It's a high-margin business, so you're right. The drop-throughs are higher. As you'd expect, over a few years in which demand from BioPharma has been weaker and we anticipated that weakness would persist for a little while, we've already dealt with the cost base. It is now highly geared towards sales growth. The margin is highly geared towards sales growth. Our target is that 30%, getting back to 30% in Watson-Marlow.
What makes that the correct goal? It isn't really that the business has undergone structural change, but we put a substantial amount of capital into going all the way back—a new plant for Aflex in Huddersfield, a new plant for BioPure in Portsmouth, and a new plant for the U.S. in the shape of Devons. What follows from that is extra depreciation across all those investments, while the earlier plants were old, had stood there for a long time, and carried very low depreciation costs. That too is having an effect on the margin. We feel comfortable with the guidance we've provided on getting back to 30%. A really quick question. Just on that point now, GBP 40 million central costs—do you view that as a sort of stable level going forward for that particular line, or does it shift around with some of these other factors?
Yeah, I think it may shift a bit around the margins, but I'd say that's fair. I don't want to provide guidance for 2026 and 2027, but my sense is the uptick comes from us kind of nurturing certain central investments, digital in particular, while those are still in that first phase. We discussed MIM at the capital markets day. Some of that early-stage investment will likely be carried over to corporate.
That's the idea behind together for growth. When you tackle these things jointly rather than attempting them three times in three separate ways, you can do them far more efficiently. You attract stronger talent. You're able to apply that expertise more effectively. You can create shared platforms instead of having to build three platforms. We'll determine what gets handled at the center versus what takes place in the business. What you're seeing is that driving the rise in central costs. Thanks. Right behind you.
Thank you. This is Martin Wilkie from Citi. I have a couple of questions about demand in a couple of areas. You clearly have exposure to traditional energy markets — both oil and gas and power gen — and also to decarbonisation. Given what's happening in the U.S., but perhaps even in other areas, is that mix shifting for you? Are you getting a sense that investments in traditional energy areas, whether in gas or traditional power gen in the U.S., are seeing lifetime extensions or expansion? Is that incrementally positive for you? On the flip side, are customer conversations about decarbonisation becoming harder? I mean, again, probably mostly U.S.-centric, but I'm just keen to hear how you're seeing that.
Sure, that's a really good question. So oil and gas probably accounts for roughly 6% of our group sales. And that's a healthy exposure for us to have. We're seeing growth in that area thanks to some of the conversations taking place around the world. At the same time, our business specifically tied to decarb is fairly small. We still have a great many customers, especially in Europe but in the U.S. as well, who are committed to hitting the targets they set out a while back and are thinking through how to get there with our products and with our expertise. We're seeing strong interest in our solutions, a pipeline of opportunities that keeps building, and solid growth in order intake in that space too. Right now, we appear to be performing well on both fronts. Another point worth keeping in mind when it comes to decarbonisation: people make decarbonisation decisions for different reasons. Sometimes it's because they want to hit their sustainability goals. When you use energy more efficiently, you also save money. So there's an efficiency driver behind making decarbonisation investments too. I don't see this as binary, right?
We're aiming for decarbonisation. Well, actually, that's simply a different lens on efficiency. Our goal is to use energy more efficiently. So how do we achieve that? Thanks. Are there any further questions? Great. Oh, apologies. We'll move to the phones. There's one online regarding capital allocation. Could you remind us what your priorities are for capital allocation, given your dividend and deleveraging ambitions? Certainly. Louisa, would you like to handle that?
Organic growth remains the main priority, along with a progressive dividend. We're still interested in bolt-on M&A where it fits our product portfolio, and then in other returns to shareholders. On deleveraging, we're really pleased that net debt has come down. We're at 1.6x EBITDA, versus 1.7x last year. We did well on working capital. We had a small working capital inflow this year. The team did really well on inventory. We'll keep that focus going. Some large deleveraging might be difficult this year, 2025, because we have to absorb the restructuring costs. We see potential for that in 2026 and 2027 as we start to grow the margin again. A team really focused on working capital. Some of the restructuring we're doing, where we've talked about clustering opcos, will mean we don't have to hold stock in as many places. Hopefully that brings some additional benefits as well.
All right. Thanks, Matt. With no further questions, I appreciate everyone being here today. Thank you very much. And thanks to all of you joining on the webcast too. We're looking forward to talking with all of you over the weeks and months ahead.
Thanks.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Spirax Group plc transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Spirax Group plc earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.